Selpercatinib
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Selpercatinib: From RET Fusion-Positive NSCLC to Pulmonary Hypertension
One-Sentence Summary
Selpercatinib is a highly selective RET tyrosine kinase inhibitor, internationally approved for RET fusion/mutation-positive non-small-cell lung cancer (NSCLC) and thyroid cancer; it is not currently marketed in Taiwan. The TxGNN model predicts it may be effective for Pulmonary Hypertension, but this signal is currently supported by zero clinical trials and zero directly relevant publications — the two literature citations retrieved concern NSCLC safety/efficacy, not pulmonary hypertension. Two additional low-confidence predictions (migraine disorder, migraine with brainstem aura) carry no supporting evidence at all.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from Taiwan licensing data (drug not marketed locally); per international approval, RET fusion/mutation-positive NSCLC and thyroid cancer |
| Predicted New Indication | Pulmonary Hypertension |
| TxGNN Prediction Score | 99.18% |
| Evidence Level | L5 |
| Taiwan Market Status | ✗ Not marketed (未上市) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is currently a data gap (DG002). Based on the available repurposing rationale, selpercatinib is a highly selective RET tyrosine kinase inhibitor, internationally approved for RET fusion/mutation-positive NSCLC and RET-driven thyroid cancers. Its efficacy in these oncology indications is well established through pivotal trials outside this evidence pack.
The link to pulmonary hypertension rests on a theoretical hypothesis: the RET/GDNF signaling axis has been associated with pulmonary vascular remodeling in some preclinical research. However, neither of the two retrieved publications addresses this pathway or pulmonary hypertension directly — both are NSCLC-focused (one comparing adverse-event profiles of RET inhibitors, the other a real-world efficacy analysis). This suggests the high TxGNN score likely arises from indirect “lung”-related node associations within the knowledge graph rather than substantive mechanistic or clinical evidence.
The two migraine-related predictions (ranks 2–3) rely on an even weaker hypothesis — RET’s role in trigeminal sensory neuron signaling — with no literature or trial evidence whatsoever. These are noted for completeness but are not prioritized further in this report.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39372206 | 2024 | Real-world/Cohort (AE profile) | Frontiers in Pharmacology | Compares adverse event profiles of pralsetinib vs. selpercatinib using FDA AERS data; safety-focused, no pulmonary hypertension relevance |
| 34178121 | 2021 | Retrospective analysis (NSCLC efficacy) | Therapeutic Advances in Medical Oncology | Real-world efficacy of selpercatinib in RET fusion-positive NSCLC (SIREN access program); no pulmonary hypertension relevance |
Note: Both publications relate to the drug’s original NSCLC indication, not the predicted pulmonary hypertension indication. No disease-specific evidence currently exists.
US Market Information
Selpercatinib is currently not marketed in Taiwan (0 licenses on record); no NDA/product data is available for review.
Cytotoxicity (Antineoplastic Drugs Only)
Selpercatinib is an antineoplastic agent (approved for RET fusion/mutation-positive NSCLC and thyroid cancer).
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (selective RET tyrosine kinase inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions — no TFDA toxicity data available (DG001) |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | General class-level considerations for RET/TKI agents (liver function, blood pressure, QTc, CBC) — not confirmed against local labeling |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information. TFDA labeling data (warnings/contraindications) is a blocking data gap (DG001) and safety cannot be evaluated until this is resolved.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is Evidence Level L5 (model prediction only) with no clinical trials and no disease-specific literature support; the retrieved publications relate to the drug’s original NSCLC indication rather than pulmonary hypertension. Combined with a blocking gap in TFDA safety data (DG001), this candidate cannot proceed to safety evaluation (S1) at this time.
To proceed, the following is needed:
- TFDA/FDA label warnings and contraindications (resolve DG001)
- Confirmed mechanism of action data via DrugBank API (resolve DG002)
- Preclinical or mechanistic evidence directly linking RET inhibition to pulmonary vascular remodeling
- Monitoring for future trial registrations targeting pulmonary hypertension
- Re-evaluation of the migraine-related predictions only if any supporting evidence emerges
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.